A phase 2 trial in triple-negative breast cancer, run by UNC Lineberger Comprehensive Cancer Center, now recruiting.
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer is a phase 2, randomised interventional study registered as NCT07276880 by UNC Lineberger Comprehensive Cancer Center, with a registry enrolment figure of 32 participants, started 2026-03-17 and due to reach its primary completion in 2027-11. Interventions recorded: Neoadjuvant Pembrolizumab; low dose neoadjuvant boost; High dose neoadjuvant boost. Conditions listed: Breast Cancer; Triple Negative Breast Cancer (TNBC); HER2-Negative Breast Carcinoma; Node-positive Breast Cancer. Sites: United States. No results are recorded here; the registry entry is the source.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.